Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Precision BioSciences (NASDAQ:DTIL – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC ...

Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B ...

Precision BioSciences (NASDAQ:DTIL – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to ...

Occult HBV infection is defined by the existence of HBV DNA in serum, lymphoid cells (PBMC) and/or the liver and virus-genome replicative intermediates (i.e., covalently closed circular DNA ...

Precision’s proprietary ARCUS genome editing platform is explained ... need for not only inactivating the HBV, but also eradicating their ccc-DNA from the patient. In this sense, PBGENE-HBV ...

Precision aims to define the optimal dose and number of administrations for the elimination of covalently closed circular DNA ... PBGENE-HBV is developed using the company’s 'Arcus' genome ...

The presence and the positioning of nucleosomes on DNA can be important in directing cellular mechanisms to transcribe some genes. We found that to be the case for the HBV gene encoding protein X — ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

On March 27, 1827, the day after Ludwig van Beethoven's death, his associates uncovered a hidden trove of documents in his desk. Among them was the Heiligenstadt Testament, a letter written in 1802 to ...